EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines

Almudena Gil-Rodriguez iD, Sheila Recarey-Rama iD, Ana Fernández Montes iD, Ana Rodríguez-Viyuela, Francisco Barros iD, Angel Carracedo iD, Olalla Maroñas

International Journal of Molecular Sciences · 22.08.2025 · 26 (17) · 8136

DOI: 10.3390/ijms26178136 ↗

Kurz gefasst

Leitlinie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.08.2025. Verfasst von Almudena Gil-Rodriguez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacogenomics and Drug Discovery Group (GenDeM), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Linkage Disequilibrium, Dihydrouracil Dehydrogenase (NADP), Dihydropyrimidine Dehydrogenase Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), European Union funds (NextGen).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluoropyrimidine derivatives can cause severe toxicity in patients with DPD deficiency. Regulatory agencies, such as the European Medicines Agency (EMA), recommend pre-emptive genotyping of the HapB3 haplotype, along with other variants. Historically, the two main HapB3 variants, the benign c.1236G>A and the pathogenic c.1129-5923C>G, have been assumed to be in complete linkage disequilibrium. Recent findings contradict this assumption, questioning the reliability of the HapB3 analysis through c.1236G>A, which could directly impact patient safety. The aim of this study is to assess the linkage disequilibrium between the c.1236G>A and c.1129-5923C>G variants, with the ultimate goal of revising genotyping guidelines. A total of 46 patients already heterozygous for the c.1236G>A variant have been carefully reviewed for the c.1129-5923C>G variant. From the 46 patients analyzed, 45 maintain complete linkage disequilibrium between both variants. However, there is one patient where this linkage disequilibrium is not complete, being heterozygous for c.1236G>A and homozygous for c.1129-5923C>G. These findings challenge the validity of c.1236G>A as a surrogate marker for pathogenic variant c.1129-5923C>G. This article highlights the need for a review of the recommendations of the EMA and suggests laboratories to analyze both variants, or at least the pathogenic one, to ensure accurate therapeutic decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Linkage DisequilibriumDihydrouracil Dehydrogenase (NADP)Dihydropyrimidine Dehydrogenase DeficiencyHumansPolymorphism, Single NucleotideHaplotypesMaleFemaleEuropePharmacogeneticsGenotypeMiddle Aged

Stichwörter der Autor:innen

5-fluorouracilDPYDHapB3 haplotypeguideline recommendationslinkage disequilibriumpathogenicregulatory agency

Substanzen

Dihydrouracil Dehydrogenase (NADP)

Autor:innen und Institutionen

  • Pharmacogenomics and Drug Discovery Group (GenDeM), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
  • Genomics and Bioinformatics Group, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Medical Oncology Department, University Hospital Complex of Ourense (CHUO), 32005 Ourense, Spain.
  • Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Galician Public Foundation of Genomic Medicine (FPGMX), Galician Healthcare Service (SERGAS), 15706 Santiago de Compostela, Spain.
  • Genetics Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.

ORCID-Profile: Almudena Gil-Rodriguez, Sheila Recarey-Rama, Ana Fernández Montes, Francisco Barros, Angel Carracedo

Förderung

  • Instituto de Salud Carlos III (ISCIII)
  • European Union funds (NextGen)

Zitieren

APA

Gil-Rodriguez, A., Recarey-Rama, S., Fernández Montes, A., Rodríguez-Viyuela, A., Barros, F., Carracedo, A., & Maroñas, O. (2025). A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines. International Journal of Molecular Sciences, 26(17), 8136. https://doi.org/10.3390/ijms26178136

Vancouver

Gil-Rodriguez A, Recarey-Rama S, Fernández Montes A, Rodríguez-Viyuela A, Barros F, Carracedo A, et al. A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines. International Journal of Molecular Sciences. 2025;26(17):8136. doi:10.3390/ijms26178136

BibTeX
@article{GilRodriguez2025,
  author = {Gil-Rodriguez, Almudena and Recarey-Rama, Sheila and Fernández Montes, Ana and Rodríguez-Viyuela, Ana and Barros, Francisco and Carracedo, Angel and Maroñas, Olalla},
  title = {A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8136},
  doi = {10.3390/ijms26178136}
}
Kostenlos starten →